# Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD

> **NCT03004417** · PHASE2 · COMPLETED · sponsor: **Chiesi Farmaceutici S.p.A.** · enrollment: 61 (actual)

## Conditions studied

- COPD

## Interventions

- **DRUG:** CHF 6001 Dose1
- **DRUG:** CHF 6001 Dose2
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03004417
- **Lead sponsor:** Chiesi Farmaceutici S.p.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-31
- **Primary completion:** 2017-12-28
- **Final completion:** 2017-12-28
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004417, "Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03004417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*